EP2675471A4 - Compositions liées à la sérumalbumine humaine et procédés d'utilisation - Google Patents

Compositions liées à la sérumalbumine humaine et procédés d'utilisation

Info

Publication number
EP2675471A4
EP2675471A4 EP11858565.2A EP11858565A EP2675471A4 EP 2675471 A4 EP2675471 A4 EP 2675471A4 EP 11858565 A EP11858565 A EP 11858565A EP 2675471 A4 EP2675471 A4 EP 2675471A4
Authority
EP
European Patent Office
Prior art keywords
hsa
methods
related compositions
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11858565.2A
Other languages
German (de)
English (en)
Other versions
EP2675471A1 (fr
Inventor
Changshou Gao
Chaity Chaudhury
Xiaotao Yao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/024855 external-priority patent/WO2011103076A1/fr
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of EP2675471A1 publication Critical patent/EP2675471A1/fr
Publication of EP2675471A4 publication Critical patent/EP2675471A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
EP11858565.2A 2011-02-15 2011-08-09 Compositions liées à la sérumalbumine humaine et procédés d'utilisation Withdrawn EP2675471A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2011/024855 WO2011103076A1 (fr) 2010-02-16 2011-02-15 Compositions relatives a l'albumine serique humaine et leurs methodes d'utilisation
PCT/US2011/047040 WO2012112188A1 (fr) 2011-02-15 2011-08-09 Compositions liées à la sérumalbumine humaine et procédés d'utilisation

Publications (2)

Publication Number Publication Date
EP2675471A1 EP2675471A1 (fr) 2013-12-25
EP2675471A4 true EP2675471A4 (fr) 2015-01-28

Family

ID=46675795

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11858565.2A Withdrawn EP2675471A4 (fr) 2011-02-15 2011-08-09 Compositions liées à la sérumalbumine humaine et procédés d'utilisation

Country Status (7)

Country Link
EP (1) EP2675471A4 (fr)
JP (1) JP2014510518A (fr)
KR (1) KR20140012094A (fr)
CN (1) CN103379915A (fr)
AU (1) AU2011359378A1 (fr)
CA (1) CA2826683A1 (fr)
WO (1) WO2012112188A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493545B2 (en) 2009-02-11 2016-11-15 Albumedix A/S Albumin variants and conjugates
MX2012004793A (es) 2009-10-30 2012-07-20 Novozymes Biopharma Dk As Variantes de albumina.
CN104610454A (zh) 2010-02-16 2015-05-13 米迪缪尼有限公司 Hsa相关组合物及使用方法
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
EP2780364A2 (fr) * 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Protéines ayant une demi-vie et d'autres propriétés améliorées
BR112014018679A2 (pt) 2012-03-16 2017-07-04 Novozymes Biopharma Dk As variantes de albumina
EP2917233A1 (fr) * 2012-11-08 2015-09-16 Novozymes Biopharma DK A/S Variants d'albumine
EP3318124A3 (fr) 2013-02-16 2018-05-30 Albumedix A/S Modèle pharmacocinétique animal
WO2014140366A1 (fr) * 2013-03-15 2014-09-18 Affibody Ab Nouveaux polypeptides
RS58164B1 (sr) * 2013-06-12 2019-03-29 Pharis Biotec Gmbh Peptidi sa antagonističkim aktivnostima prema prirodnom cxcr4
EP3044232A1 (fr) * 2013-09-13 2016-07-20 Novozymes Biopharma DK A/S Variants d'albumine
US10208102B2 (en) 2013-11-01 2019-02-19 University Of Oslo Albumin variants and uses thereof
JP6862348B2 (ja) 2015-03-12 2021-04-21 メディミューン，エルエルシー アルブミン融合タンパク質を精製する方法
US10633428B2 (en) 2015-08-20 2020-04-28 Albumedix Ltd Albumin variants and conjugates
KR20180056701A (ko) * 2015-09-23 2018-05-29 브리스톨-마이어스 스큅 컴퍼니 패스트-오프 레이트 혈청 알부민 결합 피브로넥틴 유형 iii 도메인
EP3394243A1 (fr) 2015-12-22 2018-10-31 Albumedix Ltd. Souches améliorées pour l'expression de protéines
CN110337590A (zh) 2016-11-04 2019-10-15 奥胡斯大学 以新生儿Fc受体过表达为特征的肿瘤的识别和治疗
KR102638505B1 (ko) 2017-06-20 2024-02-20 알부메딕스 리미티드 개선된 단백질 발현 스트레인
DK3717011T3 (da) 2017-11-29 2023-01-09 Csl Ltd Fremgangsmåde til behandling eller forebyggelse af iskæmi-reperfusionsskade
US20210238238A1 (en) 2018-05-16 2021-08-05 Csl Limited Soluble complement receptor type i variants and uses thereof
BR112021008105A2 (pt) 2018-10-29 2021-08-03 Biogen Ma Inc. variantes de fc5 humanizadas e estabilizadas para intensificação de transporte através de barreira hematoencefálica
CN114302896A (zh) 2019-09-06 2022-04-08 诺华股份有限公司 治疗性融合蛋白
EP4069200A1 (fr) 2019-12-04 2022-10-12 Albumedix Ltd Procédés et compositions produites par ceux-ci
WO2022166720A1 (fr) * 2021-02-05 2022-08-11 华南理工大学 Protéine de fusion à base d'albumine sérique, et nano-ensemble, son procédé de préparation et son application
CN113912730B (zh) * 2021-12-14 2022-03-04 北京科诺信诚科技有限公司 缓释的抗FcRn抗体或抗原结合片段及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103076A1 (fr) * 2010-02-16 2011-08-25 Medlmmune, Llc Compositions relatives a l'albumine serique humaine et leurs methodes d'utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9404270D0 (en) * 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs
ES2525065T3 (es) * 2008-04-11 2014-12-17 Merrimack Pharmaceuticals, Inc. Ligadores de seroalbúmina humana y sus conjugados
US20120076728A1 (en) * 2009-04-08 2012-03-29 The Regents Of The University Of California Human protein scaffold with controlled serum pharmacokinetics

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103076A1 (fr) * 2010-02-16 2011-08-25 Medlmmune, Llc Compositions relatives a l'albumine serique humaine et leurs methodes d'utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2012112188A1 *

Also Published As

Publication number Publication date
CN103379915A (zh) 2013-10-30
EP2675471A1 (fr) 2013-12-25
JP2014510518A (ja) 2014-05-01
CA2826683A1 (fr) 2012-08-23
WO2012112188A1 (fr) 2012-08-23
AU2011359378A1 (en) 2013-10-03
KR20140012094A (ko) 2014-01-29

Similar Documents

Publication Publication Date Title
EP2675471A4 (fr) Compositions liées à la sérumalbumine humaine et procédés d'utilisation
HK1193837A1 (zh) 聚脲組合物及其使用方法
SG10202009963PA (en) Melanin modification compositions and methods of use
EP2536756A4 (fr) Compositions relatives a l'albumine serique humaine et leurs methodes d'utilisation
EP2584897A4 (fr) Compositions contenant du resvératrol et procédés d'utilisation
PL3199024T3 (pl) Zastosowanie kompozycji cyklodekstryny i stosowne sposoby
HK1203049A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
EP2836218A4 (fr) Compositions prébiotiques et leurs procédés d'utilisation
HK1202244A1 (en) Prebiotic formulations and methods of use
EP2836224A4 (fr) Compositions de microbiota et leurs procédés associés
EP2678018A4 (fr) Combinaison d'inhibiteurs des kinases et utilisations associées
SG11201501499SA (en) Multi-functional compositions and methods of use
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
EP2772483A4 (fr) Compose 4-aminocarbazole et son utilisation
EP2771030A4 (fr) Compositions et méthodes de traitement de protéinopathies
EP2596112A4 (fr) Compositions d'acétylcystéine et méthodes d'utilisation correspondantes
EP2667889A4 (fr) Compositions de wnt et procédés d'utilisation de celles-ci
EP2704688A4 (fr) Compositions de cochléate et leurs procédés de fabrication et d'utilisation
IL227924A0 (en) Preparations and methods of use for determining a4he
EP2906041A4 (fr) Compositions et procédés d'utilisation d'un composé de lutte contre l'inappétence
EP2753337A4 (fr) Compositions comprenant des bêta-glucanes et leurs procédés d'utilisation
EP2755668A4 (fr) Compositions dérivées de hyr1 et méthodes de traitement les utilisant
EP2709999A4 (fr) Composés de quinazoline-7-éther et méthodes d'utilisation
EP2670245A4 (fr) Alpha-cétohétérocycles et leurs procédés de fabrication et d'utilisation
EP2668044A4 (fr) Compositions et leur utilisation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130906

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1192466

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20150108

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/765 20060101ALI20141222BHEP

Ipc: A61K 47/48 20060101ALI20141222BHEP

Ipc: A61K 38/38 20060101AFI20141222BHEP

17Q First examination report despatched

Effective date: 20150907

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160318

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1192466

Country of ref document: HK